Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Lisata Therapeutics, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05712356CT.gov A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02821754CT.gov A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bile Duct Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | Lisata Therapeutics, Inc. | P2 | B · 57 |
| Cis-Diamminedichloroplatinum Ii | Lisata Therapeutics, Inc. | P2 | BB |
| Oxaliplatin | Lisata Therapeutics, Inc. | P2 | B |
| Celecoxib | Seoul National University Hospital | P4 | B |
| Pembrolizumab | Imugene Limited | P2 | B |
| Fluorouracilum | Lisata Therapeutics, Inc. | P2 | B |
| N-Butyl Cyanoacrylate | Minia University | P3 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | National Cancer Institute (NCI) | P2 | B |
| Utidelone | Beijing Biostar Pharmaceuticals Co., Ltd. | P2 | CCC |
+21 more in the Bile Duct Cancer cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Bile Duct Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-bile-duct-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →